Novo Nordisk(US:NVO) Zhi Tong Cai Jing·2026-01-06 14:10Core Viewpoint - Novo Nordisk (NVO.US) has seen a significant stock price increase, rising over 4% in pre-market trading and accumulating an 8% increase over the previous two days, currently priced at $57.33. This surge is attributed to the announcement of the launch of two oral weight loss medications, Wegovy, for self-paying patients in the U.S. starting January 5 [1] Pricing and Product Details - The two initial dosages of Wegovy, 1.5 mg and 4 mg, will be priced at $149 per month. Additionally, two higher dosage forms, 9 mg and 25 mg, will be available at a monthly price of $299 [1] - The price for the 4 mg dosage will increase to $199 per month starting April 15 [1] Regulatory Approval and Market Position - The U.S. Food and Drug Administration (FDA) approved the oral medication Wegovy on December 22 of the previous year, providing Novo Nordisk with a renewed competitive edge against Eli Lilly (LLY.US) in the market [1]